Vivir Cream Special Precautions

Patients with immunodeficiency disease including acquired immune deficiency syndrome (AIDS) and bone marrow transplantation.
Therapy with Vivir Cream should be initiated as early as possible following onset of signs and symptoms. The recommended dosage, frequency of applications and length of treatment should not be exceeded.
Vivir Cream should not be used for the prevention of recurrent infections or the prevention of transmission of infection to other persons.
Although clinically significant viral resistance associated with the use of acyclovir cream has not been observed, this possibly exists.
Vivir Cream is intended for cutaneous use only and should not be used in the eye.
Vivir Cream is not recommended for application to mucous membranes eg, in the mouth, eye or vagina, as it may be irritant.
Particular care should be taken to avoid accidental introduction into the eye.
Use in pregnancy: Systemic administration of acyclovir in internationally accepted standard tests did not produce embryotoxic or teratogenic effects in rats, rabbits or mice.
In a non-standard test in rats, fetal abnormalities were observed, but only following such high SC doses that maternal toxicity was produced. Experience in humans is limited, so Vivir Cream should be used by a pregnant woman or possibly pregnant woman only when the expected.
Use in children: Safety and effectiveness in children have not been established.